Vivi Ann Flørenes
Position: Researcher, Ph.D.
Phone: +47 22 78 24 33
Email:
 

Author network for Vivi Ann Flørenes by COREMINE medical


Publications 2017

Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA et al. (2017)
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
ESMO Open, 2 (2), e000158
PubMed 28761742

Publications 2016

Egeland EV, Flatmark K, Nesland JM, Flørenes VA, Mælandsmo GM, Boye K (2016)
Expression and clinical significance of Wee1 in colorectal cancer
Tumour Biol, 37 (9), 12133-12140
PubMed 27220319

Fleten KG, Flørenes VA, Prasmickaite L, Hill O, Sykora J, Mælandsmo GM, Engesæter B (2016)
hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma
Cell Death Discov, 2, 16081
PubMed 28028438

Nymoen DA, Slipicevic A, Holth A, Emilsen E, Hetland Falkenthal TE, Tropé CG, Reich R, Flørenes VA, Davidson B (2016)
MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma
Hum Pathol, 54, 74-81
PubMed 27063471

Publications 2015

Flørenes VA, Emilsen E, Dong HP, Førsund M, Holm R, Slipicevic A (2015)
Cellular localization of CIP2A determines its prognostic impact in superficial spreading and nodular melanoma
Cancer Med, 4 (6), 903-13
PubMed 25663244

Magnussen GI, Emilsen E, Giller Fleten K, Engesæter B, Nähse-Kumpf V, Fjær R, Slipicevic A, Flørenes VA (2015)
Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma
BMC Cancer, 15, 462
PubMed 26054341

Publications 2014

Slipicevic A, Holth A, Hellesylt E, Tropé CG, Davidson B, Flørenes VA (2014)
Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions
Gynecol Oncol, 135 (1), 118-24
PubMed 25093290

Publications 2013

Flatmark K, Guldvik IJ, Svensson H, Fleten KG, Flørenes VA, Reed W, Giercksky KE, Fodstad Ø, Andersson Y (2013)
Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies
Int J Cancer, 133 (6), 1497-506
PubMed 23494569

Magnussen GI, Hellesylt E, Nesland JM, Trope CG, Flørenes VA, Holm R (2013)
High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients
BMC Cancer, 13, 288
PubMed 23767999

Vettukattil R, Hetland TE, Flørenes VA, Kærn J, Davidson B, Bathen TF (2013)
Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma
Hum Pathol, 44 (9), 1859-66
PubMed 23656974

Publications 2012

Engesæter B, Engebraaten O, Flørenes VA, Mælandsmo GM (2012)
Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma
PLoS One, 7 (9), e45492
PubMed 23029050

Hetland TE, Holth A, Kærn J, Flørenes VA, Tropé CG, Davidson B (2012)
HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases
Virchows Arch, 460 (5), 505-13
PubMed 22476403

Hetland TE, Kærn J, Skrede M, Sandstad B, Tropé C, Davidson B, Flørenes VA (2012)
Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index
Cancer Chemother Pharmacol, 69 (5), 1307-14
PubMed 22302409

Hetland TE, Nymoen DA, Emilsen E, Kærn J, Tropé CG, Flørenes VA, Davidson B (2012)
MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival
Gynecol Oncol, 126 (3), 460-5
PubMed 22652154

Hetland TE, Nymoen DA, Holth A, Brusegard K, Flørenes VA, Kærn J, Tropé CG, Davidson B (2012)
Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance
Hum Pathol, 44 (5), 777-85
PubMed 23114921

Magnussen GI, Holm R, Emilsen E, Rosnes AK, Slipicevic A, Flørenes VA (2012)
High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy
PLoS One, 7 (6), e38254
PubMed 22719872

Magnussen GI, Ree Rosnes AK, Shahzidi S, Dong HP, Emilsen E, Engesæter B, Flørenes VA (2012)
Synthetic retinoid CD437 induces apoptosis and acts synergistically with TRAIL receptor-2 agonist in malignant melanoma
Biochem Biophys Res Commun, 420 (3), 516-22
PubMed 22446330

Slipicevic A, Holm R, Emilsen E, Ree Rosnes AK, Welch DR, Mælandsmo GM, Flørenes VA (2012)
Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival
BMC Cancer, 12, 73
PubMed 22356677

Slipicevic A, Øy GF, Rosnes AK, Stakkestad Ø, Emilsen E, Engesæter B, Mælandsmo GM, Flørenes VA (2012)
Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis
Cancer Biol Ther, 14 (2), 146-54
PubMed 23192275

Publications 2011

Dong HP, Ree Rosnes AK, Bock AJ, Holth A, Flørenes VA, Trope' CG, Risberg B, Davidson B (2011)
Flow cytometric measurement of cellular FLICE-inhibitory protein (c-FLIP) in ovarian carcinoma effusions
Cytopathology, 22 (6), 373-82
PubMed 22032542

Engesæter BO, Sathermugathevan M, Hellenes T, Engebråten O, Holm R, Flørenes VA, Mælandsmo GM (2011)
Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells
Cancer Biol Ther, 12 (1), 47-58
PubMed 21508672

Hetland TE, Hellesylt E, Flørenes VA, Tropé C, Davidson B, Kærn J (2011)
Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance
Hum Pathol, 42 (7), 1019-26
PubMed 21315408

Publications 2010

Oy GF, Slipicevic A, Davidson B, Solberg Faye R, Maelandsmo GM, Flørenes VA (2010)
Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma
Int J Cancer, 126 (2), 350-61
PubMed 19588500

Wang Z, Trope CG, Flørenes VA, Suo Z, Nesland JM, Holm R (2010)
Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes
BMC Cancer, 10, 233
PubMed 20500813

Publications 2009

Kleinberg L, Dong HP, Holth A, Risberg B, Trope' CG, Nesland JM, Flørenes VA, Davidson B (2009)
Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma
Hum Pathol, 40 (6), 795-806
PubMed 19157506

Maelandsmo GM, Flørenes VA, Nguyen MT, Flatmark K, Davidson B (2009)
Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites
Tumour Biol, 30 (1), 15-25
PubMed 19194111

Slipicevic A, Øy GF, Askildt IC, Holth A, Hellesylt E, Flørenes VA, Davidson B (2009)
Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions
Hum Pathol, 40 (4), 527-37
PubMed 19121847

Publications 2008

Dong HP, Kleinberg L, Silins I, Flørenes VA, Tropé CG, Risberg B, Nesland JM, Davidson B (2008)
Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma
Cancer, 112 (1), 84-93
PubMed 17985388

Goscinski MA, Suo Z, Flørenes VA, Vlatkovic L, Nesland JM, Giercksky KE (2008)
FAP-alpha and uPA show different expression patterns in premalignant and malignant esophageal lesions
Ultrastruct Pathol, 32 (3), 89-96
PubMed 18570153

Goscinski MA, Suo ZH, Nesland JM, Chen WT, Zakrzewska M, Wang J, Zhang S, Flørenes VA, Giercksky KE (2008)
Seprase, dipeptidyl peptidase IV and urokinase-type plasminogen activator expression in dysplasia and invasive squamous cell carcinoma of the esophagus. A study of 229 cases from Anyang Tumor Hospital, Henan Province, China
Oncology, 75 (1-2), 49-59
PubMed 18787344

Goscinski MA, Suo ZH, Nesland JM, Flørenes VA, Giercksky KE (2008)
Dipeptidyl peptidase IV expression in cancer and stromal cells of human esophageal squamous cell carcinomas, adenocarcinomas and squamous cell carcinoma cell lines
APMIS, 116 (9), 823-31
PubMed 19024603

Odlo K, Hentzen J, dit Chabert JF, Ducki S, Gani OA, Sylte I, Skrede M, Flørenes VA, Hansen TV (2008)
1,5-Disubstituted 1,2,3-triazoles as cis-restricted analogues of combretastatin A-4: Synthesis, molecular modeling and evaluation as cytotoxic agents and inhibitors of tubulin
Bioorg Med Chem, 16 (9), 4829-38
PubMed 18396050

Slipicevic A, Jørgensen K, Skrede M, Rosnes AK, Trøen G, Davidson B, Flørenes VA (2008)
The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells
BMC Cancer, 8, 276
PubMed 18826602

Torlakovic EE, Slipicevic A, Flørenes VA, Chibbar R, DeCoteau JF, Bilalovic N (2008)
Fli-1 expression in malignant melanoma
Histol Histopathol, 23 (11), 1309-14
PubMed 18785112

Publications 2007

Davidson B, Hadar R, Schlossberg A, Sternlicht T, Slipicevic A, Skrede M, Risberg B, Flørenes VA, Kopolovic J, Reich R (2007)
Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma
Hum Pathol, 39 (1), 87-95
PubMed 17949781

Davidson B, Skrede M, Silins I, Shih IeM, Trope CG, Flørenes VA (2007)
Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma
Cancer, 110 (6), 1264-71
PubMed 17647260

Kleinberg L, Flørenes VA, Nesland JM, Davidson B (2007)
Survivin, a member of the inhibitors of apoptosis family, is down-regulated in breast carcinoma effusions
Am J Clin Pathol, 128 (3), 389-97
PubMed 17709312

Kleinberg L, Flørenes VA, Silins I, Haug K, Trope CG, Nesland JM, Davidson B (2007)
Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma
Cancer, 109 (2), 228-38
PubMed 17167759

Kleinberg L, Lie AK, Flørenes VA, Nesland JM, Davidson B (2007)
Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma
Hum Pathol, 38 (7), 986-94
PubMed 17350081

Publications 2006

Davidson B, Espina V, Steinberg SM, Flørenes VA, Liotta LA, Kristensen GB, Tropé CG, Berner A, Kohn EC (2006)
Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling
Clin Cancer Res, 12 (3 Pt 1), 791-9
PubMed 16467090

Davidson B, Zhang Z, Kleinberg L, Li M, Flørenes VA, Wang TL, Shih IeM (2006)
Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma
Clin Cancer Res, 12 (20 Pt 1), 5944-50
PubMed 17062665

Jørgensen K, Davidson B, Flørenes VA (2006)
Activation of c-jun N-terminal kinase is associated with cell proliferation and shorter relapse-free period in superficial spreading malignant melanoma
Mod Pathol, 19 (11), 1446-55
PubMed 16951673

Kleinberg L, Flørenes VA, Skrede M, Dong HP, Nielsen S, McMaster MT, Nesland JM, Shih IeM, Davidson B (2006)
Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma
Virchows Arch, 449 (1), 31-9
PubMed 16541284

Torlakovic E, Slipicevic A, Robinson C, DeCoteau JF, Alfsen GC, Vyberg M, Chibbar R, Flørenes VA (2006)
Pax-5 expression in nonhematopoietic tissues
Am J Clin Pathol, 126 (5), 798-804
PubMed 17050077

Publications 2005

Agesen TH, Flørenes VA, Molenaar WM, Lind GE, Berner JM, Plaat BE, Komdeur R, Myklebost O, van den Berg E, Lothe RA (2005)
Expression patterns of cell cycle components in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors
J Neuropathol Exp Neurol, 64 (1), 74-81
PubMed 15715087

Jørgensen K, Skrede M, Cruciani V, Mikalsen SO, Slipicevic A, Flørenes VA (2005)
Phorbol ester phorbol-12-myristate-13-acetate promotes anchorage-independent growth and survival of melanomas through MEK-independent activation of ERK1/2
Biochem Biophys Res Commun, 329 (1), 266-74
PubMed 15721302

Schaner ME, Davidson B, Skrede M, Reich R, Flørenes VA, Risberg B, Berner A, Goldberg I, Givant-Horwitz V, Tropè CG, Kristensen GB, Nesland JM, Børresen-Dale AL (2005)
Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients
Mol Cancer, 4, 26
PubMed 16042759

Slipicevic A, Holm R, Nguyen MT, Bøhler PJ, Davidson B, Flørenes VA (2005)
Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome
Am J Clin Pathol, 124 (4), 528-36
PubMed 16146807

Ødegaard E, Staff AC, Kaern J, Flørenes VA, Kopolovic J, Tropé CG, Abeler VM, Reich R, Davidson B (2005)
The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma
Gynecol Oncol, 100 (3), 462-8
PubMed 16216317

Publications 2004

Andersen K, Nesland JM, Holm R, Flørenes VA, Fodstad Ø, Maelandsmo GM (2004)
Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma
Mod Pathol, 17 (8), 990-7
PubMed 15133476

Davidson B, Alejandro E, Flørenes VA, Goderstad JM, Risberg B, Kristensen GB, Trope CG, Kohn EC (2004)
Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma
Cancer, 100 (10), 2139-47
PubMed 15139056

Davidson B, Reich R, Lazarovici P, Flørenes VA, Risberg B, Nielsen S, Sert B, Bedrossian C (2004)
Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma
Lung Cancer, 44 (2), 159-65
PubMed 15084380

Flørenes VA, Maelandsmo GM, Holm R, Reich R, Lazarovici P, Davidson B (2004)
Expression of activated TrkA protein in melanocytic tumors: relationship to cell proliferation and clinical outcome
Am J Clin Pathol, 122 (3), 412-20
PubMed 15362372

Flørenes VA, Skrede M, Jørgensen K, Nesland JM (2004)
Deacetylase inhibition in malignant melanomas: impact on cell cycle regulation and survival
Melanoma Res, 14 (3), 173-81
PubMed 15179185

Torlakovic EE, Bilalovic N, Nesland JM, Torlakovic G, Flørenes VA (2004)
Ets-1 transcription factor is widely expressed in benign and malignant melanocytes and its expression has no significant association with prognosis
Mod Pathol, 17 (11), 1400-6
PubMed 15205685

Publications 2003

Davidson B, Reich R, Lazarovici P, Nesland JM, Skrede M, Risberg B, Tropé CG, Flørenes VA (2003)
Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma
Clin Cancer Res, 9 (6), 2248-59
PubMed 12796393

Jørgensen K, Holm R, Maelandsmo GM, Flørenes VA (2003)
Expression of activated extracellular signal-regulated kinases 1/2 in malignant melanomas: relationship with clinical outcome
Clin Cancer Res, 9 (14), 5325-31
PubMed 14614017

Maelandsmo GM, Holm R, Nesland JM, Fodstad Ø, Flørenes VA (2003)
Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma
Clin Cancer Res, 9 (9), 3383-8
PubMed 12960126

Skotheim RI, Abeler VM, Nesland JM, Fosså SD, Holm R, Wagner U, Flørenes VA, Aass N, Kallioniemi OP, Lothe RA (2003)
Candidate genes for testicular cancer evaluated by in situ protein expression analyses on tissue microarrays
Neoplasia, 5 (5), 397-404
PubMed 14670177

Sudbø J, Reith A, Flørenes VA, Nesland JM, Ristimäki A, Bryne M (2003)
COX-2 expression in striated muscle under physiological conditions
Oral Dis, 9 (6), 313-6
PubMed 14629333

Publications 2002

Meza-Zepeda LA, Forus A, Lygren B, Dahlberg AB, Godager LH, South AP, Marenholz I, Lioumi M, Flørenes VA, Maelandsmo GM, Serra M, Mischke D, Nizetic D, Ragoussis J, Tarkkanen M, Nesland JM, Knuutila S, Myklebost O (2002)
Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21
Oncogene, 21 (14), 2261-9
PubMed 11948409

Ree AH, Bratland A, Kroes RA, Aasheim HC, Flørenes VA, Moskal JR, Fodstad O, Bruland OS, Maelandsmo GM (2002)
Clinical and cell line specific expression profiles of a human gene identified in experimental central nervous system metastases
Anticancer Res, 22 (4), 1949-57
PubMed 12174869

Publications 2001

Davidson B, Risberg B, Berner A, Nesland JM, Tropé CG, Kristensen GB, Bryne M, Goscinski M, van de Putte G, Flørenes VA (2001)
Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications
Gynecol Oncol, 83 (2), 249-56
PubMed 11606079

Flørenes VA, Maelandsmo GM, Faye R, Nesland JM, Holm R (2001)
Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome
J Pathol, 195 (5), 530-6
PubMed 11745687

Forus A, D'Angelo A, Henriksen J, Merla G, Maelandsmo GM, Flørenes VA, Olivieri S, Bjerkehagen B, Meza-Zepeda LA, del Vecchio Blanco F, Müller C, Sanvito F, Kononen J, Nesland JM, Fodstad Ø, Reymond A, Kallioniemi OP, Arrigoni G, Ballabio A, Myklebost O, Zollo M (2001)
Amplification and overexpression of PRUNE in human sarcomas and breast carcinomas-a possible mechanism for altering the nm23-H1 activity
Oncogene, 20 (47), 6881-90
PubMed 11687967

Holm R, Skovlund E, Skomedal H, Flørenes VA, Tanum G (2001)
Reduced expression of p21WAF1 is an indicator of malignant behaviour in anal carcinomas
Histopathology, 39 (1), 43-9
PubMed 11454043

Publications 2000

Flørenes VA, Faye RS, Maelandsmo GM, Nesland JM, Holm R (2000)
Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma
Clin Cancer Res, 6 (9), 3614-20
PubMed 10999753

Publications 1999

Easty DJ, Hill SP, Hsu MY, Fallowfield ME, Florenes VA, Herlyn M, Bennett DC (1999)
Up-regulation of ephrin-A1 during melanoma progression
Int J Cancer, 84 (5), 494-501
PubMed 10502726

Flørenes VA, Lu C, Bhattacharya N, Rak J, Sheehan C, Slingerland JM, Kerbel RS (1999)
Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma
Oncogene, 18 (4), 1023-32
PubMed 10023678

Rak J, Mitsuhashi Y, Sheehan C, Krestow JK, Florenes VA, Filmus J, Kerbel RS (1999)
Collateral expression of proangiogenic and tumorigenic properties in intestinal epithelial cell variants selected for resistance to anoikis
Neoplasia, 1 (1), 23-30
PubMed 10935467

Publications 1998

Flørenes VA, Maelandsmo GM, Kerbel RS, Slingerland JM, Nesland JM, Holm R (1998)
Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival
Am J Pathol, 153 (1), 305-12
PubMed 9665492

St Croix B, Sheehan C, Rak JW, Flørenes VA, Slingerland JM, Kerbel RS (1998)
E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1)
J Cell Biol, 142 (2), 557-71
PubMed 9679152

Publications 1997

Easty DJ, Mitchell PJ, Patel K, Flørenes VA, Spritz RA, Bennett DC (1997)
Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK in metastatic melanoma
Int J Cancer, 71 (6), 1061-5
PubMed 9185712

Holm R, Flørenes VA, Erikstein B, Nesland JM (1997)
Expression of stromelysin-3 in medullary carcinoma of the breast
Anticancer Res, 17 (5B), 3725-7
PubMed 9427769

Maelandsmo GM, Flørenes VA, Mellingsaeter T, Hovig E, Kerbel RS, Fodstad O (1997)
Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma
Int J Cancer, 74 (4), 464-9
PubMed 9291441

Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O (1997)
High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases
Clin Cancer Res, 3 (9), 1623-8
PubMed 9815852

Publications 1996

Flørenes VA, Bhattacharya N, Bani MR, Ben-David Y, Kerbel RS, Slingerland JM (1996)
TGF-beta mediated G1 arrest in a human melanoma cell line lacking p15INK4B: evidence for cooperation between p21Cip1/WAF1 and p27Kip1
Oncogene, 13 (11), 2447-57
PubMed 8957087

Kerbel RS, St Croix B, Florenes VA, Rak J (1996)
Induction and reversal of cell adhesion-dependent multicellular drug resistance in solid breast tumors
Hum Cell, 9 (4), 257-64
PubMed 9183656

Maelandsmo GM, Flørenes VA, Hovig E, Oyjord T, Engebraaten O, Holm R, Børresen AL, Fodstad O (1996)
Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas
Br J Cancer, 73 (8), 909-16
PubMed 8611425

Maelandsmo GM, Holm R, Fodstad O, Kerbel RS, Flørenes VA (1996)
Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions
Am J Pathol, 149 (6), 1813-22
PubMed 8952518

Maelandsmo GM, Hovig E, Skrede M, Engebraaten O, Flørenes VA, Myklebost O, Grigorian M, Lukanidin E, Scanlon KJ, Fodstad O (1996)
Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme
Cancer Res, 56 (23), 5490-8
PubMed 8968106

St Croix B, Flørenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM, Kerbel RS (1996)
Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents
Nat Med, 2 (11), 1204-10
PubMed 8898746

Publications 1995

Flørenes VA, Holm R, Fodstad O (1995)
Accumulation of p53 protein in human malignant melanoma. Relationship to clinical outcome
Melanoma Res, 5 (3), 183-7
PubMed 7640520

Maelandsmo GM, Berner JM, Flørenes VA, Forus A, Hovig E, Fodstad O, Myklebost O (1995)
Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas--relationship to amplification and mRNA levels of CDK4 and CCND1
Br J Cancer, 72 (2), 393-8
PubMed 7640224

Wen DY, Hall WA, Conrad J, Godal A, Flørenes VA, Fodstad O (1995)
In vitro and in vivo variation in transferrin receptor expression on a human medulloblastoma cell line
Neurosurgery, 36 (6), 1158-63; discussion 1163-4
PubMed 7643997

Publications 1994

Flørenes VA, Holm R, Myklebost O, Lendahl U, Fodstad O (1994)
Expression of the neuroectodermal intermediate filament nestin in human melanomas
Cancer Res, 54 (2), 354-6
PubMed 8275467

Flørenes VA, Maelandsmo GM, Forus A, Andreassen A, Myklebost O, Fodstad O (1994)
MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status
J Natl Cancer Inst, 86 (17), 1297-302
PubMed 8064888

Flørenes VA, Oyjord T, Holm R, Skrede M, Børresen AL, Nesland JM, Fodstad O (1994)
TP53 allele loss, mutations and expression in malignant melanoma
Br J Cancer, 69 (2), 253-9
PubMed 7905277

Forus A, Flørenes VA, Maelandsmo GM, Fodstad O, Myklebost O (1994)
The protooncogene CHOP/GADD153, involved in growth arrest and DNA damage response, is amplified in a subset of human sarcomas
Cancer Genet Cytogenet, 78 (2), 165-71
PubMed 7828148

Kashani-Sabet M, Funato T, Florenes VA, Fodstad O, Scanlon KJ (1994)
Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme
Cancer Res, 54 (4), 900-2
PubMed 8313379

Publications 1993

Andreassen A, Oyjord T, Hovig E, Holm R, Flørenes VA, Nesland JM, Myklebost O, Høie J, Bruland OS, Børresen AL (1993)
p53 abnormalities in different subtypes of human sarcomas
Cancer Res, 53 (3), 468-71
PubMed 8425179

Forus A, Flørenes VA, Maelandsmo GM, Meltzer PS, Fodstad O, Myklebost O (1993)
Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: some amplica do not include MDM2
Cell Growth Differ, 4 (12), 1065-70
PubMed 8117620

Publications 1992

Flørenes VA, Aamdal S, Myklebost O, Maelandsmo GM, Bruland OS, Fodstad O (1992)
Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression
Cancer Res, 52 (21), 6088-91
PubMed 1356624